This HTML5 document contains 33 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n10http://linked.opendata.cz/resource/drugbank/drug/DB05398/identifier/drugbank/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n7http://linked.opendata.cz/resource/drugbank/drug/DB05398/identifier/chemspider/
n9http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
n11http://linked.opendata.cz/resource/drugbank/drug/DB05398/identifier/pubchem-compound/
xsdhhttp://www.w3.org/2001/XMLSchema#

Statements

Subject Item
n2:DB05398
rdf:type
n3:Drug
n3:description
C31G is a potent broad spectrum antimicrobial agent, effective against gram positive and gram negative bacteria, yeast and fungi.C31G, vaginal gel is developed by Biosyn Inc. and has commenced enrollment in a phase III pivotal clinical trial for the reduction of sexual transmission of human immunodeficiency virus (HIV).
n3:generalReferences
# Barnhart KT, Pretorius ES, Timbers K, Shera D, Shabbout M, Malamud D: Distribution of a 3.5-mL (1.0%) C31G vaginal gel using magnetic resonance imaging. Contraception. 2005 May;71(5):357-61. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15854637
n3:group
investigational
n3:indication
Investigated for use/treatment in contraception, HIV infection, and prevention of stdis.
owl:sameAs
n9:DB05398
dcterms:title
C31G
adms:identifier
n7:401828 n10:DB05398 n11:456362
n3:mechanismOfAction
The range of organisms killed by C31G has been extended to include enveloped viruses. Coupled with data indicating a low toxicity for mammalian cells, and a much wider range of anti-microbial activity than Nonoxynol-9, it appears that C31G is an ideal agent for use in decreasing the risk of transmission of organisms associated with STD. C31G is developed as a topical vaginal microbicide with broad-spectrum antibacterial and antiviral properties. C31G which has a high affinity for bacteria, fungi, yeast, and viruses while exhibiting low mammalian cell toxicity.
n3:IUPAC-Name
n4:271B428B-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B4291-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B4290-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B428D-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B428E-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B428F-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B428A-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B4297-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B4298-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B4292-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B4293-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B4295-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B4294-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B4296-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B429C-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B429E-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B429F-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B429B-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B429A-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B429D-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B428C-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B4299-363D-11E5-9242-09173F13E4C5